Electronic cigarette (e-cigarette) use is rapidly increasing, with many users reporting trying e-cigarettes as a method to quit combustible cigarettes. This review highlights recently published studies assessing the use of e-cigarettes as a tool for cessation of combustible cigarettes.
INTRODUCTION
Electronic cigarettes (e-cigarettes), also known as electronic nicotine delivery systems, are batteryoperated devices, which deliver nicotine by heating and aerosolizing a nicotine-containing solution. E-cigarettes have three key components: a power source, an electronic heating element, and liquidcontaining nicotine cartridge. The liquid in the cartridge contains varying concentrations of nicotine and flavorings in a stabilizing liquid vehicle. When the user activates the heating element, a nicotine-containing liquid aerosolizes and is subsequently inhaled [1, 2] . E-cigarettes have been marketed as an alternative to traditional combustible cigarettes. E-cigarettes became available in the United States in 2007 with increasing awareness and popularity, leading to approximately 15% of US adults in 2014 reporting trying an e-cigarette [1, 3, 4] . Current smokers and those reporting recent cessation comprise the largest fraction of e-cigarette users, with approximately 50% of these groups in the United States, and 40% in the Great Britain reporting use [3] [4] [5] . Among both current and former smokers, the most commonly cited reasons for the use of e-cigarettes were perceived health benefits when compared with combustible cigarettes, followed by assistance with smoking cessation [5] . These epidemiological data highlight that e-cigarette users are integrating these devices as a smoking cessation tool. What remains unclear is whether the current state of scientific evidence supports this social phenomenon. The purpose of this review is to summarize the recent literature regarding the efficacy of e-cigarettes to impact smoking cessation. With these data, clinicians, policymakers, and e-cigarette users can better understand the potential role of e-cigarettes in smoking cessation.
Any consideration of e-cigarettes as a cessation tool must incorporate a discussion of the known harms of these devices. Heterogeneity in e-cigarette device design leads to substantial heterogeneity in vapor constituents [2, 6] . Vapor analysis of 12 brands of e-cigarettes revealed the presence of many toxic chemicals including carbonyl compounds, volatile organic compounds, carcinogenic nitrosamines, and heavy metals [7] . These toxins were present at concentrations 9-450 times lower than that seen in cigarette smoke. Recent studies have reported that superheating of glycol derivatives, achievable with newer higher voltage 'tank' devices, increases the generation of potentially carcinogenic carbonyl compounds [8] . Although the preponderance of data support that e-cigarettes generate toxic compounds at levels less than combustible cigarettes, it is unclear if these levels are below a threshold for harm. Moreover, given the relative infancy of e-cigarette use, it will likely be decades before longterm harm data are available. These uncertainties have been used as evidence by both proponents and opponents of e-cigarettes to support their claims of benefits or harms.
RANDOMIZED CONTROLLED TRIALS OF ELECTRONIC CIGARETTES FOR CESSATION
Currently, there are limited clinical trials to assist healthcare providers when counseling patients on the role of e-cigarettes as a cessation tool. Four randomized controlled trials (RCTs) have directly studied e-cigarettes usage for smoking cessation [9 & ,10-12] (Table 1 ). The largest study was conducted by Bullen et al. [11] in New Zealand between 2011 and 2013. This study recruited 657 smokers interested in quitting to receive low-intensity behavioral support along with either 16 mg nicotine e-cigarette, 21 mg nicotine patch, or placebo e-cigarette for 6 months. Biochemically verified abstinence at 6 months was the primary outcome. At 6 months, there was no difference in the biochemically confirmed smoking abstinence: 7.3% nicotine e-cigarette, 5.8% nicotine patch, 4.1% placebo e-cigarette (nicotine versus placebo e-cigarette P ¼ 0.44; nicotine e-cigarette versus patch P ¼ 0.46). Notably, 57% of patients in the nicotine e-cigarette decreased their daily number of cigarettes smoked by at least half compared with 41% of participants randomized to nicotine patch (P ¼ 0.0002).
The 2013 'Efficiency and Safety of an Electronic Cigarette as Tobacco Cigarettes Substitute' study by Caponnetto et al. [10] randomized 300 Italian smokers not interested in quitting to either 7.2 mg e-cigarette for 12 weeks, 7.2 mg e-cigarette for 6 weeks then 5.4 mg e-cigarette for 6 weeks, or 0 mg e-cigarette for 12 weeks. After 12 weeks, participants were advised to continue using their e-cigarette if they wished, but no additional cartridges were provided by investigators. Participants were subsequently followed for an additional 40 weeks. At the end of the study period of 52 weeks, overall cessation rates were 11% in the 7.2 mg group, 13% in the 5.4 mg group, and 4% in the placebo group (P ¼ 0.24 for overall difference). At 52 weeks, 9-12% of smokers in all three groups had reduced their baseline cigarette usage by half with no significant differences between groups.
A 2014 RCT by Adriaens et al. [12] randomized 48 smokers who were not wanting to quit to either a control group with no intervention, or to one of two different brands of refillable second-generation e-cigarettes with 18 mg nicotine-containing solution. The primary aim of the study was to evaluate acute cravings over a span of 8 weeks in relation to successful sustained smoking reduction. An e-cigarette group was permitted to use the device for 8 weeks, whereas the control group was asked to avoid e-cigarettes. All groups were followed for 6 months after the 8-week study. At 6 months, cessation rates were 19% for the e-cigarette group and 25% for the control group (P value for difference not provided). A total of 60% fewer cigarettes were smoked per day across all groups; however, only 23% participants had a greater than 50% reduction in number of cigarettes smoked.
The most recently published RCT by Tseng et al. [9 nicotine e-cigarette or placebo e-cigarette, and then followed for 3 weeks. They were not offered other nicotine replacement therapy, and were excluded if already on nicotine replacement therapy. Formal assessment of cessation was not a prespecified outcome of this study, but no participants reported complete cessation at follow-up. After 3 weeks, there was a significant reduction in cigarettes per day smoked in both groups (P < 0.001). The odds of achieving at least 50% reduction in users of nicotine e-cigarettes was 3.2-fold greater than placebo e-cigarettes (P ¼ 0.034).
So how are we to incorporate these data into an assessment of the value of e-cigarettes as a cessation tool? Taken individually or in total, the available RCTs demonstrate that e-cigarettes are no better and no worse than placebo or nicotine replacement as a tool for smoking cessation. However, all RCTs are limited by variable outcome assessments, inadequate sample size, and diverse study populations of smokers. The most recent Cochrane review published in September 2016 found that data pooled from the studies by Bullen et al. [11] and Caponnetto et al. [10] support an effect of nicotine e-cigarettes on cessation when compared with placebo e-cigarettes, but grades the confidence in these conclusions as low given the few trials, low event rates, and wide confidence intervals (CIs) [13 && ]. The study by Bullen et al. [11] is the only RCT to compare e-cigarettes with standard nicotine replacement therapy, which is the most relevant comparator for clinicians. Unfortunately, the fixed dose nicotine replacement used in that study has been shown to be less effective than dual replacement approached (i.e., patch and gum) [14, 15] . Moreover, the trial design placed the nicotine replacement group at a disadvantage compared with the e-cigarette group, as the nicotine replacement group was given vouchers for patches, whereas the e-cigarette group was directly provided e-cigarettes. It is tempting to speculate that e-cigarettes may have been less effective than nicotine replacement if these study weaknesses were not present. Despite this, Bullen et al. [11] should be commended for embarking on a rigorous and relevant comparator design. Study designs comparing established cessation practices should be a focus of future randomized control trials as to obtain the most clinically relevant data.
COHORT STUDIES OF ELECTRONIC CIGARETTES FOR CESSATION
Given that conclusive data from RCTs is unlikely to be available in the near future, clinicians may look to data from observational studies to derive conclusions about the role of e-cigarettes for cessation. Although these data do not meet the 'gold standard' of scientific proof attributed to RCTs, they are informative in that these study designs are more reflective of the real-world setting. A recent nonrandomized trial from London included offering e-cigarettes to all smokers seeking help from the UK's Stop Smoking Services [16 & ]. E-cigarettes were offered in addition to the standard treatment of behavioral support and medications. Of 100 smokers, 69 opted in for e-cigarette use. In addition to e-cigarette use, 20 participants also opted to use varenicline, whereas 23 opted to use nicotine replacement therapy. Of those who trialed ecigarettes, 68% reported cessation in the e-cigarette group at 4-week follow-up compared with 45% of smokers not using e-cigarettes (P ¼ 0.06). There was a significantly higher cessation in smokers who used varenicline and e-cigarette compared with those using e-cigarette alone (85 versus 54%; P ¼ 0.03). The higher rates of cessation using a multifaceted approach suggest that combination therapy which incorporates e-cigarettes with non-nicotine pharmacotherapy warrants additional exploration. ] surveyed 1374 US smokers at baseline and 2-3 years later (51% retention rate). Self-reported 1-month cessation rates were 12% for e-cigarette nonusers, 9% for nondaily e-cigarette users, and 20% for daily e-cigarette users (overall P ¼ 0.50). In adjusted analyses, compared with nonusers, regular e-cigarette users were six times more likely to quit smoking (OR 6.07; 95% CI 1.11-33.2). No association was observed between nondaily e-cigarette use and cessation. These results are consistent with a previously published cohort study of 1549 US smokers, which observed that e-cigarette use as baseline was not associated with cessation 1 year later (OR 0.71; 95% CI 0.35-1.46; P ¼ 0.35) [19] .
Two UK cohort studies have shown that ecigarettes are associated with increased cessation of combustible cigarettes [20, 21 && ]. Brown et al. [20] enrolled 5863 participants in a retrospective cross-sectional study in England evaluating adults who had attempted to quit smoking within the past 12 months. Participants were asked about their number of quit attempts, use of nicotine replacement therapy, use of e-cigarettes, and smoking urges. Nonsmoking was reported among 20% of e-cigarette users, 10% of nicotine replacement users, and 15% of those using no aid. Use of e-cigarettes increased the odds of self-reported abstinence compared with nicotine replacement therapy (OR 2.23; 95% CI 1.70-2.93) or no cessation aid (OR 1.38; 95% CI 1.08-1.76). The association between e-cigarette use and self-reported abstinence persisted after adjusting for potential confounders, including age, sex, social grade, nicotine dependence, and prior quit attempts. Extrapolated data from this study estimates that 19 000-22 000 long-term quitters were generated with the assistance from e-cigarettes [22] . Recently, Beard et al. [21 && ] reported findings from 1200 smokers in the UK Smoking Toolkit Study, a cross-sectional population-based survey. In 2016, 21% of the cohort reported using e-cigarettes and 18.6% reported successful quit attempts. Self-reported success rates of quit attempts increased by 0.98% for every 1% increase in prevalence of e-cigarette use (95% CI 0.64-1.32%; P < 0.001). E-cigarette use during a quit attempt was associated with 0.58% increase in successful quit attempts for every 1% increase in e-cigarette use (95% CI 0.38-0.78%; P < 0.001).
The recent cohort studies have yielded conflicting results, with some demonstrating no differential impact on smoking cessation rates, whereas others have demonstrated efficacy. The cohort studies suffer the limitations inherent in cohort studies, namely observational design without standardized interventions, self-reported outcomes, and low retention rates.
CONCLUSION
When assessing the preponderance of available data regarding e-cigarettes and smoking cessation, it is evident that these devices are not clearly superior to approved nicotine replacement therapy or 'usual care.' Importantly however, the current data also show that these devices are not clearly inferior to approved nicotine replacement therapy or 'usual care.' This counterpoint highlights the need for equipoise when evaluating e-cigarettes as a potential cessation tool. Pooled data from the available studies demonstrates no increased serious adverse events related to e-cigarettes for up to 2 years of follow-up [13 && ]. Longer term safety is not known. Although inconclusive, the currently available data informs several realities of e-cigarettes in the cessation landscape:
(1) E-cigarette use is rapidly increasing and most prevalent among current smokers. (2) E-cigarettes are no more or less effective than nicotine replacement therapy for cessation. Interpretations of the currently available date regarding e-cigarettes for cessation differ widely by medical and regulatory bodies [23] [24] [25] [26] [27] . Public Health England (PHE) has issued a statement encouraging the use of e-cigarettes for smokers who could not, or would not, quit smoking tobacco [28 && ,29] . PHE supported the reduced harm approach by providing an estimate of e-cigarettes being 95% safer than cigarette smoking [28 && ]. Additionally, Action on Smoking Health, UK's public health charity that focuses on eliminating the harm caused by tobacco, has denounced the notion that e-cigarettes act as a gateway drug to cigarette use [29] . This is in contrast to the recommendations from US regulatory bodies, including the US Preventive Services Task Force and Centers for Disease Control and Prevention, recommending against the use of e-cigarettes for cessation given insufficient data [24, 30] . These discrepant messages, derived from assessment of the same body of data, only contribute to the confusion for clinicians, smokers, and e-cigarette users. It is possible that these differing regional guidelines will provide a natural experiment at the global level regarding the impact of e-cigarettes on cessation, as is currently being observed with the recent UK publications [20, 21 && ]. In summary, regarding e-cigarettes for smoking cessation, are we there yet? The simple answer is no. However, researchers, policymakers and e-cigarette users must reassess what level of evidence will get us there. Definitive RCTs will continue to be difficult to design, will require replication, and may never give a conclusive answer to individuals without equipoise on this issue. Cohort studies, although convenient, will also lack definitive findings. Long-term studies, required to understand harms of e-cigarettes, will not be forthcoming in the near future. Meanwhile, e-cigarette use by tobacco smokers as a cessation tool is likely to continue to increase. As shared decisionmaking is becoming the new standard of care for medical treatments, it is imperative to engage e-cigarette users in the scientific process. Researchers should engage e-cigarette users to ensure appropriate study designs, which replicate real-world use, perhaps abandoning rigid RCTs for rigorous population-level cohort studies. Clinicians' discussions with users should include clear explanations of the certainties and uncertainties surrounding e-cigarettes. It is our practice to recommend approved cessation therapies (e.g., nicotine replacement therapy, varenicline) for individuals inquiring about e-cigarettes. Only if patients have failed these therapies, or are unwilling to try them, do we then discuss e-cigarettes as a bridge to complete cessation. Policymakers should embrace equipoise when interpreting the potential benefits and harms of e-cigarettes. As the scientific knowledge about e-cigarettes and cessation accumulates, all stakeholders should balance the uncertainty of unknown harms of e-cigarettes with the known harms of continued combustible cigarette use.
